Cynthia Trickett, MPAS, PA-C, and Leigh Ann Pansch, MSN, FNP-BC, DCNP, discussed recognizing hidradenitis suppurativa early, screening for comorbidities, and assessing disease burden.

Cosibelimab (Unloxcyt; Sun Pharma), a PD-L1 inhibitor, is also approved for locally advanced and metastatic cutaneous ...

Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult ...

On this episode of Don't Be Rash, Andrew Krakowski, MD, spoke with Sheilagh Maguiness, MD, about the FDA's approval of bemotrizinol and what the new sunscreen filter means for pediatric patients. On ...

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in ...

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis. A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found ...

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of ...

Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.

Dr. Bunick introduces the panel's second case: a 72-year-old retired school administrator with plaque psoriasis diagnosed at ...

Symptomatic dermographism has its first on-label treatment. Here’s what APPs should know about recognition, treatment, and remibrutinib.

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research. Glynis ...

The DecisionDx-Melanoma 31-GEP test recently released top data from the largest prospective GEP study. The study was ...